LBPMedicine(SH:688393)2025-04-29 09:03Financial Performance - The company's revenue for Q1 2025 was ¥72,543,474.19, a decrease of 28.51% compared to ¥101,468,637.22 in the same period last year[3] - The net profit attributable to shareholders was -¥11,064,498.81, representing a decline of 238.49% from ¥7,989,313.63 in the previous year[3] - The basic earnings per share were -¥0.12, a decline of 233.33% from ¥0.09 in the same period last year[3] - The diluted earnings per share were also -¥0.12, down 250.00% from ¥0.08 in the previous year[4] - Net profit for Q1 2025 was a loss of ¥12,249,821.81, compared to a profit of ¥3,781,976.65 in Q1 2024[15] - The net profit attributable to shareholders of the parent company for Q1 2025 was a loss of ¥11,064,498.81, compared to a profit of ¥7,989,313.63 in Q1 2024[17] Cash Flow - The net cash flow from operating activities improved to ¥3,888,748.24, a significant increase of 115.89% compared to -¥24,475,755.67 in the same period last year[3] - Cash inflow from operating activities in Q1 2025 was ¥106,136,985.63, slightly up from ¥105,904,561.62 in Q1 2024[18] - Cash outflow from operating activities in Q1 2025 was ¥102,248,237.39, down from ¥130,380,317.29 in Q1 2024[18] - The net cash flow from operating activities was $3,888,748.24, a decrease of $24,475,755.67 compared to the previous period[19] - The net cash flow from financing activities was -$5,601,723.19, compared to -$20,374,537.97 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,329,718,266.26, a decrease of 2.42% from ¥1,362,730,307.94 at the end of the previous year[4] - The company's current assets totaled RMB 652,395,028.10, down from RMB 692,252,007.28, indicating a decrease of about 5.8%[12] - Cash and cash equivalents decreased significantly from RMB 95,146,930.50 to RMB 48,058,624.00, representing a decline of approximately 49.5%[11] - The company's total liabilities decreased from RMB 130,988,198.25 to RMB 109,729,311.26, a decline of about 16.2%[13] - The company's equity remained stable with total equity at RMB 1,219,988,955.00 as of March 31, 2025[13] Research and Development - Research and development expenses totaled ¥10,765,339.05, accounting for 14.84% of revenue, an increase of 3.78 percentage points from 11.06% in the previous year[4] - Research and development expenses for Q1 2025 were ¥9,284,399.55, an increase of 6.2% from ¥8,740,663.97 in Q1 2024[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,309[8] - The company has not reported any significant changes in shareholder structure or participation in margin trading activities during the reporting period[10] Other Financial Metrics - The weighted average return on equity was -0.88%, a decrease of 1.51 percentage points from 0.63% in the previous year[4] - The company reported non-recurring gains and losses totaling ¥1,903,245.37 for the period[5] - The company experienced a credit impairment loss of ¥1,143,895.30 in Q1 2025, compared to a gain of ¥1,881,551.59 in Q1 2024[15] - The company reported a significant increase in sales expenses, totaling ¥37,379,708.06 in Q1 2025, compared to ¥43,232,342.70 in Q1 2024[14] Investment Activities - The total cash inflow from investment activities was $111,653,702.20, up from $55,249,254.58 in the prior period[19] - The net cash outflow from investment activities was $43,628,071.03, a significant decline from a net inflow of $25,539,718.26 previously[19] Accounting Standards - The company will not apply new accounting standards starting from 2025[20]